Please login to the form below
abiraterone
This page shows the latest abiraterone news and features for those working in and with pharma, biotech and healthcare.
Daily Brief: NICE says no to Zytiga, Genentech and UK biotech sign microbiome deal
families. “We firmly believe that the clinical effectiveness demonstrated in the multinational, Phase 3 LATITUDE study, means that abiraterone plus ADT should be made available routinely to NHS patients that need
Latest news
-
EMA starts review of Xtandi in non-metastatic prostate cancer
At the moment Xtandi - like longstanding rival Zytiga (abiraterone acetate) from Johnson &Johnson - is only prescribed for men with advanced CRPC that has spread and no longer responds to hormone therapy.
-
J&J’s Erleada first US drug for non-metastatic prostate cancer
momentum before Zytiga (abiraterone acetate) - its current blockbuster medicine for CRPC - faces generic competition in the US, which accounted for around half of the drug’s $2.5bn in sales in
-
PROSPER data reveal big Xtandi benefit in early-stage prostate cancer
At the moment Xtandi, in common with a rival therapy from Johnson &Johnson called Zytiga (abiraterone acetate), is only prescribed for men with advanced CRPC that has spread and no longer ... Pfizer’s chief operating officer Albert Bourla told analysts
-
EC expands Janssen’s prostate cancer drug reach
Janssen has chalked up a significant win in the European market following a ruling on its prostate cancer drug Zytiga (abiraterone acetate), receiving the go-ahead to add an earlier stage
-
CHMP recommends Teva's generic version of Astellas' Advagraf
Finally, both Roche and Janssen got the nod for wider licences for Pegasys (peginterferon) and Zytiga (abiraterone acetate), respectively.
More from news
Approximately 5 fully matching, plus 64 partially matching documents found.
Latest Intelligence
-
Deal Watch May 2016
outperforming J&J's Zytiga [abiraterone].
-
Taking a strategic approach
But in oncology Zytiga (abiraterone) was last year not recommended for an early use indication in final draft guidance from NICE, but that appraisal process is currently on hold after Janssen
-
Pharma deals during October 2013
AstraZeneca is focusing on developing its regional oncology portfolio as evidenced by the closure of a co-promotion deal with Janssen in Japan for Zytiga (abiraterone acetate), an innovative oral therapy
-
Interview: Cesar Rodriguez, Janssen
Janssen is developing its strengths in other areas too, and Rodriguez noted the company's recent developments in oncology, including the launch of abiraterone acetate for prostate cancer – it's “ a
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Featured jobs
-
Senior Account Manager
-
Competitive salary commensurate with experience
-
Client Services Director - Med Comms
-
Great salary and bebefits
- Business Unit Head, Medical Communications, London
-
Excellent package
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
- Senior Project Manager - Medical Writing
-
Great salary and bebefits
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
Subscribe to our email news alerts
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- GSK sells eczema and psoriasis drug to Dermavant for £250m
- Moving annual total (MAT)
- Roche keeps Venclexta train rolling with new leukaemia filing
- NHS England says yes to Roche's Hemlibra
- Daily Brief: Trump arrives in London, NICE says no to Darzalex, Pfizer backs down on prices
- Daily Brief: success for Pfizer and Lilly arthritis drug, Darzalex soars, IMI launches Accelerator
- Brexit rebels win vote on European Medicines Agency alignment
- Data Visualisation
- The True Potential of Mobile Health Tech
- NHS England to Vertex: come clean on Orkambi offer
- Novartis follows Pfizer and freezes US prices this year
PMHub
emotive.
emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...
Latest intelligence
- Developing advocacy in the pharmaceutical industry.
- The importance of advocacy programmes...
- GDPR and events. What does the pharma industry need to know?
- Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
Quick links
Infographics
